Leadership Overview
Crinetics Pharmaceuticals has 6 executives leading key functions including financial strategy, medical affairs, operational management, human resources, legal compliance, and alliance oversight.
Focused on developing innovative therapies for endocrine diseases, Crinetics Pharmaceuticals prioritizes effective disease control and patient simplicity while building sustainable value for investors through targeted market solutions.
Focused on developing innovative therapies for endocrine diseases, Crinetics Pharmaceuticals prioritizes effective disease control and patient simplicity while building sustainable value for investors through targeted market solutions.
Leadership Roles at Crinetics Pharmaceuticals
Tobin Schilke - Chief Financial Officer
Tobin Schilke, the Chief Financial Officer at Crinetics Pharmaceuticals, directs all fiscal planning and capital allocation strategies. Managing the financial health of the organization, the Chief Financial Officer ensures alignment between research investments and long-term market growth. This leadership role involves overseeing investor relations and maintaining the capital structure necessary to support the development of endocrine disease therapies. By optimizing resource distribution, Tobin Schilke directly impacts the ability of the company to scale operations across North American markets. The Chief Financial Officer collaborates with the board to evaluate risk profiles and financial performance metrics. Through rigorous oversight of budgetary processes, Schilke secures the necessary funding to advance the clinical pipeline. This financial discipline supports the broader mission of delivering effective disease control to patients while maximizing shareholder value through consistent operational efficiency and strategic fiscal management.
Niccole Le - Chief of Staff To the Chief Operating Officer and Head of Alliance Management
Niccole Le, the Chief of Staff To the Chief Operating Officer and Head of Alliance Management at Crinetics Pharmaceuticals, architects the operational framework for external partnerships and internal efficiency. Overseeing the management of strategic alliances, the Chief of Staff To the Chief Operating Officer and Head of Alliance Management ensures that collaborative efforts align with the core mission of developing endocrine disease treatments. This leadership role involves coordinating with the Chief Operating Officer to optimize internal workflows and resource utilization. By fostering strong relationships with external partners, Niccole Le expands the reach of the company into new therapeutic markets. The Head of Alliance Management monitors partnership performance to ensure that joint ventures deliver maximum value to patients and investors. Through meticulous project management and strategic oversight, Le drives the execution of complex operational goals. This role remains vital for maintaining the agility required to navigate the evolving pharmaceutical landscape.
Rafael Marino - Affairs Operations Senior Director, Medical & Chief of Staff
Rafael Marino, the Affairs Operations Senior Director, Medical & Chief of Staff at Crinetics Pharmaceuticals, manages the integration of medical strategy with internal operational workflows. Coordinating cross-functional initiatives, the Affairs Operations Senior Director, Medical & Chief of Staff ensures that clinical insights inform the broader corporate agenda. This leadership role involves streamlining communication between medical teams and executive leadership to accelerate the development of endocrine therapies. By refining internal processes, Rafael Marino enhances the efficiency of medical affairs operations across global research sites. The Chief of Staff facilitates high-level decision-making by synthesizing complex data into actionable strategic plans. Through the management of key medical partnerships, Marino supports the delivery of therapies that address unmet patient needs. This operational focus ensures that the company maintains a competitive edge in the pharmaceutical industry while upholding the highest standards of medical integrity and patient-centered care.
Natalie Berwald - Executive Assistant To the Chief Human Resources Officer
Natalie Berwald, the Executive Assistant To the Chief Human Resources Officer at Crinetics Pharmaceuticals, coordinates the administrative functions that support the human capital strategy. Facilitating the daily operations of the human resources department, the Executive Assistant To the Chief Human Resources Officer ensures that talent acquisition and employee development programs remain aligned with corporate objectives. This leadership role involves managing complex scheduling, departmental communications, and the logistical requirements of the human resources team. By streamlining administrative workflows, Natalie Berwald enables the Chief Human Resources Officer to focus on high-level organizational culture and workforce planning. The Executive Assistant To the Chief Human Resources Officer maintains the integrity of sensitive personnel data while supporting the recruitment of top-tier talent needed to advance endocrine research. Through proactive support and organizational management, Berwald contributes to the overall stability and growth of the company workforce, ensuring that internal teams remain focused on delivering innovative patient therapies.
Adriana Cabre - Chief Human Resources Officer
Adriana Cabre, the Chief Human Resources Officer at Crinetics Pharmaceuticals, directs the talent strategy and organizational development initiatives. Cultivating a high-performance culture, the Chief Human Resources Officer ensures that the workforce possesses the expertise required to advance complex endocrine therapies. This leadership role involves designing compensation structures, performance management systems, and recruitment strategies that attract industry-leading professionals. By aligning human capital with the strategic goals of the company, Adriana Cabre drives innovation and operational excellence across all departments. The Chief Human Resources Officer collaborates with the executive team to foster an environment of inclusivity and professional growth. Through the implementation of robust training programs, Cabre prepares the organization for future market expansion and clinical success. This focus on people-centric management supports the broader mission of solving real problems for healthcare practitioners and patients, ensuring that the company maintains a talented and motivated team capable of achieving long-term success.
Garlan Adams - Chief Legal Officer
Garlan Adams, the Chief Legal Officer at Crinetics Pharmaceuticals, manages all legal affairs, intellectual property protection, and regulatory compliance. Safeguarding the assets of the company, the Chief Legal Officer ensures that all research and development activities adhere to global pharmaceutical standards. This leadership role involves navigating complex regulatory environments to facilitate the approval and commercialization of endocrine disease therapies. By providing strategic legal counsel, Garlan Adams mitigates risk and supports the long-term viability of the corporate pipeline. The Chief Legal Officer oversees contract negotiations and corporate governance, ensuring that all business practices align with ethical and legal requirements. Through the protection of proprietary technology, Adams secures the competitive advantage of the company in the global market. This legal oversight remains essential for maintaining the trust of healthcare practitioners and investors, ultimately supporting the mission of delivering effective disease control to patients through rigorous compliance and strategic risk management.
Explore Leadership Teams in Business Services
Founded in 1978, Promega is a manufacturer of enzymes and other products for biotechnology and molecular biology with a portfolio covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity. The company is headquartered in Madison, Wisconsin.
Company Leadership
DS
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...
Company Leadership
SK
MA
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.
Company Leadership GA
MM
VK
Frequently Asked Questions Regarding Crinetics Pharmaceuticals Top Executives and Leadership Team
Unlock more people and company data
